Loading…
Based on limited metadata available, this Warning Letter was issued to Reproductive Technologies, Inc., a biologics manufacturer, on November 6, 2019. Without access to the subject line or full letter text, the specific violations cannot be definitively characterized, though the warning falls under FDA's biologics regulatory authority. The company manufactures products in the reproductive health sector, which typically includes assisted reproductive technology products and related biologics. Additional information would be needed to determine the precise nature of the compliance issues cited in this enforcement action.